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ABSTRACT 
The Lee Silverman Voice Treatment (LSVT™) has received much attention in the past 
decade for its use in the treatment of individuals with Parkinson’s disease (Jones, 2005; Ramig, 
Countryman, O'Brien, Hoehn, & Thompson, 1996; Ramig, Sapir, Countryman et al., 2001; 
Wohlert, 2004). This intensive program requires therapy four times a week for four weeks in 
order to improve perceptual characteristics of the voice, such as loudness. However, since 
LSVT
TM
 was introduced, the rehabilitation industry has experienced systematic reductions in 
allowable frequency and duration of covered services.  The result has been that individuals often 
cannot qualify for the rigorous LSVT
TM
 protocol (Centers for Medicare and Medicaid Services, 
2008).  
The present study followed the standard treatment protocol but manipulated the dose of 
treatment to determine if a reduced dose of treatment would be effective for individuals with PD 
(IwPD) and dysarthria.  Our treatment schedule used frequency, intensity, and duration variables 
that more closely mirrored the current state of clinical practice (e.g., 45 minutes, 2 times per 
week for 8 weeks). Two IwPD participated in the study and demonstrated improvements in 
maximum vocal SPL, but these gains were not maintained at a 6-month follow-up. Treatment 
outcomes indicated improvement in body structure/function as evidenced by increased vocal 
SPL by both participants across all three speech tasks. Speech intelligibility scores and 
communicative effectiveness ratings also improved for one participant. Results, though 
preliminary, indicated a reduced dosage of the LSVT
TM
 protocol does exhibit treatment efficacy 
and treatment outcomes comparable to the original, intensive LSVT
TM
 protocol, thus moving this 
treatment closer to determining the most clinically feasible and client-friendly version of 
LSVT
TM
. 
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LITERATURE REVIEW 
Parkinson’s disease (PD) is a chronic and progressive neurological condition that is 
associated with the depletion of dopaminergic cells in the substantia nigra. Dopamine plays a 
crucial role in the production of smooth, purposeful movements, and deficiency of it results in 
the disinhibition of motor movements, including motor speech movements (Bhatnagar, 2008).  
The most common speech complaints described by individuals with Parkinson’s disease (IwPD) 
include quiet or weak voice, speaking rate that is too fast, difficulty getting speech started, or 
speech that is indistinct. These symptoms are typically labeled as hypokinetic dysarthria, which 
is the most common motor speech disorder of PD (Duffy, 2005).  Hypokinetic dysarthria not 
only affects basic properties of the individual’s speech, but it can also impact the ability to 
engage in daily activities or participate successfully in social situations. Historically, however, 
only 3-4% of IwPD presenting with voice or speech problems receive speech therapy (Fox, 
Morrison, Ramig, & Sapir, 2002) even though approximately 50% of IwPD develop speech 
difficulties (National Institute of Neurological Disorders and Stroke, 2006). In the past decade, 
evidence has begun to build around a treatment known as the Lee Silverman Voice Treatment 
(LSVT™) that is suggested to directly target voice and speech difficulties in IwPD (Ramig, 
Bonitati, Lemke, & Horii, 1994). Since the emergence of the LSVT
TM
 findings, multiple other 
studies have attempted to refine the key principles, therapy targets, and definite outcomes of this 
treatment (Baumgartner, Sapir, & Ramig, 2001; El Sharkawi et al., 2002; Ramig, Sapir, Fox, & 
Countryman, 2001; Sapir, Spielman, Ramig, Story, & Fox, 2007). However, the original 
LSVT
TM
 protocol, four times per week for four weeks, has remained unchanged since its 
inception. With the rules and regulations imposed by third party payers, alterations in the therapy 
protocol must be made so that more individuals may benefit from this treatment. Recently, 
researchers have attempted to alter the dosage of LSVT
TM
 to discover a protocol that maintains 
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original treatment effects while providing a regimen that is more closely aligned with current 
clinical practices than the original LSVT
TM
 protocol (Spielman, Ramig, Halpern, & Gavin, 2007; 
Wohlert, 2004).  
The current study’s purpose was to analyze the effect of a dosage variable on the 
treatment efficacy of LSVT
TM
 in an effort to find the most clinically feasible and client-friendly 
treatment protocol. The study was founded on several areas of research that follow. I will first 
discuss the importance of the World Health Organization’s (WHO) International Classification 
of Functioning, Disability, and Health (ICF) as it pertains to PD and the treatment of this disease. 
In the second and third sections, I will describe PD and discuss the characteristics of the 
dysarthria that typically accompany PD. In the final two sections, I will discuss LSVT
TM
 and the 
modifications that have been made to the original protocol.   
ICF Model of Rehabilitation 
The World Health Organization’s International Classification of Functioning, Disability, 
and Health (ICF) provides a unified framework for rehabilitation therapists to utilize for 
assessment and treatment of individuals with motor speech disorders. The ICF advocates for 
clinicians and researchers to shift focus from cause of the disorder to impact of the disorder on 
various aspects of the client’s life (World Health Organization, 2001). Furthermore, the ICF 
delineates multiple types of disabilities that an individual with a motor speech disorder may 
encounter. More specifically, the ICF focuses on three domains, body structure and function, 
activity limitations, and participation restrictions. The body structure/function domain 
incorporates the current level of structure/function post-onset of disease or injury, and as it 
applies to dysarthria, it includes the “slow, weak, imprecise, and/or uncoordinated movements of 
the speech musculature” that may affect respiration, phonation, resonance, and/or articulation 
(Yorkston, 1996, p. S46). Activity limitations include the individual’s difficulties in executing 
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specific tasks/actions (WHO, 2001), and as it relates to dysarthria, it includes the production of 
abnormal prosody and a reduction of speech intelligibility and speaking rate (Yorkston, 1996). 
“Problems an individual may experience in involvement in life situations” (WHO, 2001, p. 121) 
are addressed under participation restrictions, and as it relates to dysarthria, it includes 
difficulties communicating effectively in social or vocational activities. In addition to these 
domains, the ICF also considers environmental and personal factors, such as the physical 
features of the environment, family, gender, and personal habits, which represent the individual’s 
background and may impact the individual’s state of health. Research has shown that  
rehabilitation is a complex, dynamic, and multifactor phenomena, and as such, improvement in 
one domain of the ICF does not always generalize to other domains (Brandt & Pope, 1997).  
Therefore, it is crucial for treatments to target each of the domains and for outcomes to measure 
abilities within those respective domains. However, most studies of dysarthria, including the 
studies that will be reviewed here, have not incorporated this model into their treatment outcome 
measures. Furthermore, in this era of managed care, it is becoming increasingly important to not 
only address impairment level issues but also to address activity and participation limitations for 
reimbursement purposes (Donovan, Kendall, Young, & Rosenbek, 2008; Yorkston, 1996).  
Parkinson’s Disease 
The impairment, activity limitations, and participation restrictions that IwPD face are due 
to the loss of dopaminergic cells in the substantia nigra. This alteration in neurotransmitter 
availability has been found to also affect structures that are connected to the substantia nigra, 
such as the globus pallidus, putamen, and frontal lobe (Murray & Clark, 2006). Although PD is 
typically considered a disorder of movement, impaired cognition and dementia manifest in 72% 
and 10-30% of cases, respectively, because of connections between the substantia nigra and 
these other structures (Duffy, 2005; Morris & Iansek, 1996). PD often presents with a host of 
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other impairments such as dysphagia in 40-80% of cases and depression in 40-60% of cases 
(Duffy, 2005). 
The characteristic movement impairments of IwPD include hypokinesia, bradykinesia, 
tremor, rigidity, and postural instability. Hypokinesia is the reduction in overall amplitude and 
speed of movements; bradykinesia refers to the difficulty and slowness in initiating movements; 
tremors manifest as trembling hands, legs, arms, or head; rigidity refers to the characteristic 
stiffness of the trunk and limbs or resistance to movement; and postural instability is 
characterized by difficulty sustaining balance and by a stooped posture (Bhatnagar, 2008; 
Murray & Clark, 2006; Watts & Koller, 2004). These motor impairments, especially hypokinesia 
and bradykinesia, are often exaggerated in well learned movement patterns, such as speaking and 
walking, or in complex, coordinated movements (Morris & Iansek, 1996). In the majority of 
cases, etiology is unknown, though some cases appear to be due to genetic mutations, via either 
inheritance or environmental toxins (Murray & Clark, 2006). Prevalence rates estimate that PD 
currently affects over half a million individuals in the United States (NINDS, 2006).   
Hypokinetic Dysarthria 
The motor impairments caused by PD often affect verbal output resulting in speech that is 
characteristic of hypokinetic dysarthria. This type of dysarthria is a motor speech disorder 
associated with pathology of the basal ganglia control circuit, which results in problems with 
verbal communication because of weakness or incoordination of the speech musculature. In fact, 
PD is the prototypic disease associated with hypokinetic dysarthria (Duffy, 2005). Voice, 
articulation, and prosody are the components of speech that are most affected in hypokinetic 
dysarthria. Perceptual characteristics include breathiness, short rushes of speech, variable 
speaking rate with an increased overall speaking rate, reduced stress and loudness, monotonicity, 
and imprecise consonants; all of which reflect the effects of impaired movement associated with 
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PD on speech (Duffy, 2005; Weismer, 2007). These speech characteristics often affect speech 
intelligibility, which is “the extent to which a listener understands the speech produced by 
individuals with motor speech disorders” (Yorkston, Beukelman, Strand, & Bell, 1999, p. 486). 
In fact, in a retrospective review performed by the Mayo Clinic from 1969-1990 and 1999-2001, 
over 75% of IwPD and hypokinetic dysarthria had reduced speech intelligibility (Duffy, 2005). 
Lee Silverman Voice Treatment 
In an attempt to remediate some of the deficits prevalent in IwPD and dysarthria, Ramig 
and colleagues have developed a treatment targeting the respiratory and phonatory impairments 
common to PD (Countryman & Ramig, 1993; Countryman, Ramig, & Pawlas, 1994; Ramig et 
al., 1994; Ramig et al., 1996). The approach, Lee Silverman Voice Treatment (LSVT™), focuses 
on “increasing vocal intensity by increasing phonatory effort” (Ramig, Countryman, Thompson, 
& Horii, 1995, p. 1233). Lee Silverman Voice Treatment aims to remediate the common speech 
characteristics in hypokinetic dysarthria, such as breathiness, reduced loudness, and 
monotonicity, through activities designed to reduce rigidity of the laryngeal and/or respiratory 
muscles, to increase respiratory support, and to increase vocal fold adduction (Ramig, 
Countryman et al., 1995). Essential principles of this treatment include specific focus on 
increasing vocal loudness, multiple repetitions of high effortful productions, intense dosage of 
treatment (i.e., 4 sessions per week for 4 weeks), calibration of sensory awareness for self-
monitoring of vocal loudness, and behavior quantification (Ramig, Pawlas, & Countryman, 
1995). Researchers have built an extensive body of evidence for LSVT
TM
 over the past 15 years 
that provides Level I evidence (i.e., “strong evidence from at least one systematic review of 
multiple well-designed randomized controlled trials”;  Moore, McQuay, & Gray, 1995, p. 1) for 
both short-term and long-term treatment outcomes (Sapir et al., 2007). Treatment effects include 
increased phonatory loudness during sustained vowel phonation, reading of a standardized 
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passage, production of a short monolog, and a picture description task; increased subglottal 
pressure; improved vocal fold adduction; increased duration of maximum sustained vowel; 
increased fundamental frequency range; increased fundamental frequency variability in speech; 
increased vowel space; and improved oropharyngeal swallow function (El Sharkawi et al., 2002; 
Jones, 2005; Ramig, Countryman et al., 1995; Spielman, Ramig, Story, & Fox, 2000). Additional 
effects of LSVT
TM
 include perceptual reports of increased vocal loudness and speech 
intelligibility (Ramig, 1992) and anecdotal reports of reduced impact of the disorder on the 
ability to communicate (Ramig, Countryman et al., 1995).  
Although a large base of scientific evidence has formed in support of LSVT
TM
, this 
therapy is not without criticisms. Weaknesses in regards to the methodology of previous 
LSVT
TM
 studies include small sample sizes of participants, a lack of randomized participant 
selection, and poorly matched experimental and control groups (Deane, Whurr, Playford, Ben-
Shiomo, & Clarke, 2004a, 2004b). Because of these weaknesses, critics argue that the efficacy of 
this treatment cannot be made with complete confidence. Additionally, in order to provide 
LSVT
TM
 to clients, clinicians are required to become certified by attending LSVT
TM
 workshops, 
and thus, “only those who have paid their fees are in a position to add to the database” of 
LSVT
TM
 clinical outcomes research (Peach, 2004, p. 2). Inherent in this arrangement are biases 
of the clinical researcher that can only be addressed by implementing external controls into the 
study, a solution that has not been documented in previous LSVT
TM
 research (Deane et al., 
2004a). 
Another criticism revolves around the intensity, frequency, and duration of therapy 
sessions as outlined in the LSVT
TM
 protocol. As is noted in the essential principles of LSVT
TM
, 
treatment effects come by way of an intensive therapy regimen of 4 sessions per week for 4 
weeks, totaling 16 sessions. This rigorous protocol is consistent with principles of exercise, 
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learning of motor patterns/movements, and acquisition of skills (Brown, McCartney, & Sale, 
1990; Maas et al., 2008; Schmidt & Lee, 1999). However, the question of optimal procedures of 
LSVT
TM
 has yet to be fully answered by the existing body of research. Modifications of the 
LSVT
TM
 protocol’s intensity of treatment dosage “will help to elucidate the best mode of 
administration for optimal treatment results” (Fox et al., 2002, p. 114). Not only are changes in 
intensity of treatment protocol important for determining optimal treatment procedures, but the 
rehabilitation industry has experienced systematic reductions in allowable frequency and 
duration of covered services (Centers for Medicare and Medicaid Services, 2008). However, the 
original LSVT
TM
 protocol was developed prior to current reimbursement practices (e.g., payers 
may limit treatment to 45-minute sessions, two times per week for eight weeks), which has 
resulted in fewer individuals qualifying for treatment and in a lack of reimbursement for the 
practicing clinician. 
Modifications to LSVT
TM
 Protocol 
In an attempt to address questions about the efficacy of LSVT
TM
 with modified intensity, 
frequency, and duration, Wohlert (2004) varied LSVT
TM
 schedules for 11 IwPD and hypokinetic 
dysarthria to determine if treatment outcome variables were affected by altering frequency and 
duration of the therapy sessions. Participants were placed into one of three treatment schedules: 
four times per week for four weeks (i.e., normal LSVT
TM
 protocol), two times per week for eight 
weeks (i.e., same frequency; doubled duration), and two times per week for four weeks (i.e., 
frequency reduced by half; same duration). While treatment schedules differed among 
participants, all participants were assigned 40 homework sessions of an unspecified length (see 
Table 1). The therapy protocol followed the original LSVT
TM
 program (Ramig, Pawlas et al., 
1995). Outcome measures were taken prior to therapy, at the conclusion of therapy, and 3-
months after therapy ceased. Measures included forced vital capacity, vocal sound pressure level 
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(SPL) and duration of sustained phonation, vocal SPL during reading of “The Grandfather 
Passage” (Darley, Aronson, & Brown, 1975), pitch range, and Sickness Impact Profile (SIP).  
Results indicated that all participants, regardless of treatment schedule, increased in average 
vocal SPL during reading of “The Grandfather Passage” and 9 of the 11 increased in maximum 
vocal SPL during sustained phonation. At the 3-month follow-up, 9 of the 11 showed a slight 
decrease in vocal SPL, but it remained above pre-treatment levels for 8 of those 9 participants. 
Seven of the 11 participants showed a decrease in duration of sustained phonation from pre- to 
post-treatment, and pitch range did not increase for 9 of the 11 participants. Additional variables 
such as depression scores, hearing and memory acuity, years post-onset, and Hoehn & Yahr 
stage (Hoehn & Yahr, 1967) had no consistent or significant effect on treatment outcomes. The 
results from this study were in agreement with previous studies analyzing the effect of LSVT
TM
 
under original protocol intensities (Ramig, Countryman et al., 1995). From these results, the 
author suggested that the total amount of practice is more significant in producing treatment 
effects than the amount of time spent in one-on-one individual therapy sessions.  
However the issue of homework that was required of the participants in this study was 
not fully addressed. The author reported that all participants were assigned an equal amount of 
homework sessions across the three groups, yet the amount of homework assigned, as well as the 
amount of homework actually completed by each participant was not revealed. Differences in 
amount of homework time completed among participants could have led to drastic differences in 
actual amount of practice time. If the author’s argument is that LSVTTM is effective because of 
the total amount of practice time completed by the participant, that time should have been clearly 
defined. 
Furthermore, Spielman and colleagues (2007) analyzed the effect of LSVT
TM
 under the 
following extended conditions (LSVT-X): two times per week for eight weeks with 96 
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Table 1 
Comparison of treatment and homework schedules between LSVT
TM
 (Ramig, Pawlas et al., 
1995) and Wohlert (2004). 
 
Treatment Frequency  Duration  Total treatment hours Homework 
LSVT
TM
 4x/week 4 weeks 16 hours 40 assignments ranging 
from 5-30 minutes 
Wohlert (2004)     
Group 1 4x/week 4 weeks 16 hours 
40 assignments of 
unspecified length 
Group 2 2x/week 8 weeks 16 hours 
Group 3 2x/week 4 weeks 8 hours 
 
homework assignments. This study differed from the original LSVT
TM
 protocol in two ways, the 
duration of the program was doubled and the amount of homework assigned to each participant 
was more than doubled (i.e., LSVT
TM
: 40 homework assignments; LSVT-X: 96 homework 
assignments) (see Table 2). Participants included 12 individuals with idiopathic PD and speech 
characteristics “typical of PD,” as determined by three experienced speech-language 
pathologists. The therapy protocol followed the original LSVT
TM
 program (Ramig, Pawlas et al., 
1995). Outcome measures were averaged across two days of evaluation at three points: pre-
therapy, immediately post-therapy, and at 6-months following therapy cessation. Measures 
included average vocal SPL of sustained phonation, reading of the Rainbow Passage (Fairbanks, 
1960), description of a picture, and production of a spontaneous speech sample, as well as 
listener perception of quality of voice, clarity of articulation, and production of rate, intonation, 
and naturalness during the paragraph reading task. Results indicated a significant increase in 
vocal SPL on all tasks across all participants from pre-therapy to post-therapy and from pre-
therapy to follow-up, with an insignificant decrease from post-therapy to follow-up. These 
10 
 
results were compared to results from a previous LSVT
TM
 study (Ramig, Sapir, Fox et al., 2001) 
and revealed no statistically significant differences in vocal SPL among the tasks, except for the 
picture description task (i.e., higher average vocal SPL for LSVT-X). Additionally, there was no 
statistically significant difference in functional communication improvement, as indicated on the 
Voice Handicap Index (Jacobson et al., 1997). In regards to the listener perception measure, 
results indicated that speech post-therapy was “better” than speech pre-therapy. In conclusion, 
the authors noted that LSVT-X results in significant changes, comparable to LSVT
TM
, because it 
allows for more time to learn and perfect new motor programs associated with this treatment 
program and to practice newly acquired skills for longer periods of time, thereby increasing 
opportunities for generalization. These conclusions conform to motor learning theory in regards 
to distributed practice, large practice amount, variable practice contexts, and external attentional 
focus (Maas et al., 2008).  
However, this LSVT-X protocol places a burden on clinicians and clients alike because 
of the tremendous, long-term workload created by the homework assignments (Spielman et al., 
2007). These assignments are not only work for the clients, but each assignment results in more 
unbillable time a clinician must spend in creating carryover tasks.  
LSVT
TM
 was originally developed based on principles of motor learning, but it did not 
investigate a minimal optimum dosage for treatment effect. While still using principles of motor 
learning (i.e., distributed practiced, large practice amount, variable practice contexts, and 
external attentional focus), the aim of the current study was to follow the standard treatment 
protocol of LSVT
TM
 but to manipulate the dose of treatment to determine if a reduced dose of 
treatment would be effective for IwPD and dysarthria.  The modifications that were made to the 
original LSVT
TM
 protocol included the use of frequency, intensity, and duration variables that 
more closely mirror the current state of clinical practice as well as a reduction in homework 
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Table 2 
Comparison of treatment and homework schedules among LSVT
TM
 (Ramig, Pawlas et al., 1995), 
Wohlert (2004), and LSVT-X (Spielman et al., 2007). 
 
Treatment Frequency  Duration  Total treatment hours Homework 
LSVT
TM
 4x/week 4 weeks 16 hours 40 assignments ranging 
from 5-30 minutes 
Wohlert (2004)      
Group 1 4x/week 4 weeks 16 hours 
40 assignments of 
unspecified length 
Group 2 2x/week 8 weeks 16 hours 
Group 3 2x/week 4 weeks 8 hours 
     
LSVT-X 2x/week 8 weeks 16 hours 96 assignments ranging 
from 5-30 minutes 
 
assignments, perhaps yielding the most clinically feasible and client-friendly protocol of this 
treatment. The research questions to be answered were: 
1. Is there a change in vocal sound pressure level (SPL) following an 8-week bout of 
a maximum performance speech therapy (a modified version of LSVT
TM
)? 
2. Is treatment effect maintained at 6 months post-treatment? 
3. Does this dosage produce changes in vocal SPL comparable to increases observed 
in previous LSVT
TM
 studies? 
4. Is there a change in speech intelligibility scores following this treatment protocol? 
5.  Is there a change in communicative effectiveness ratings following this treatment 
protocol? 
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METHODS 
This was a multiple single-subject study on the treatment effect of maximum 
performance speech therapy for IwPD and dysarthria. The Louisiana State University (LSU) 
Institutional Review Board for the protection of human subjects approved the study proposal 
prior to enrollment of subjects and data collection. Informed consent was collected from all 
participants. 
Subjects 
Two subjects, one male (P01) and one female (P02), presenting with Parkinson’s disease 
and dysarthria were recruited for this study from the Baton Rouge Parkinson's Disease Support 
Group based on the following inclusion criteria: (1) PD diagnosis (as diagnosed by a 
neurologist), (2) dysarthria (as confirmed by a speech-language pathologist), (3) no history of or 
evidence of neurologic or neurodegenerative disease other than PD, (4) a Mini Mental State 
Examination (Folstein, Folstein, & McHugh, 1975) score > 24, (5) an Apathy Scale (Starkstein 
et al., 1992) rating > 14, (6) a Geriatric Depression Scale (GDS) Short Form (Sheikh & 
Yesavage, 1986) score of >10, (7) a Hoehn & Yahr Rating of Parkinson’s disease (Hoehn & 
Yahr, 1967) between 1 and 4, (8) a Dysarthria Severity Rating (Yorkston et al., 1999) between 
1and 4, and (9) adequate hearing as determined by patient report and conversational interaction. 
Subjects were excluded from the current study due to (1) dementia, (2) apathy, or (3) depression.  
Design 
The present study utilized a single-subject A-B-A-A repeated-probe design for each of 
the participants to examine the effects of a reduced dose of LSVT
TM
 in IwPD and dysarthria. In 
order to answer the experimental questions, the study investigated the effect of reduced treatment 
dosage on vocal SPL during sustained phonation, paragraph reading, and monologue, as well as 
speech intelligibility and communicative effectiveness. The dependent variable was maximum 
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vocal SPL during sustained vowel phonation. Pre-test, post-test, and follow-up primary outcome 
measures included average vocal SPL during sustained vowel phonation, reading of “The 
Grandfather Passage” (Darley et al., 1975), and two-minute monologue. Administered 
concomitantly with primary outcome measures, the secondary outcome measures included the 
Sentence Intelligibility portion of the Assessment of Intelligibility of Dysarthric Speech (AIDS; 
Yorkston, Beukelman, & Traynor, 1984) and the Communicative Effectiveness Survey (CES; 
Donovan et al., 2008).   
The secondary outcome measures that were used in this study have established validity 
and reliability. The AIDS is a widely used tool for determining speech intelligibility in connected 
speech and provides a measure that effectively addresses the activity domain of the ICF model 
(Yorkston et al., 1984). The CES is an 8-item, 4-unit rating scale used to assess functional 
communication in individuals with dysarthria, and research provides evidence of face validity, 
content validity, and construct validity (Donovan et al., 2008). Additionally, the CES provides a 
measure that effectively addresses the participation domain of the ICF model (Donovan et al., 
2008). Along with the primary outcome measures, which address the body structure/function 
domain, the present study allowed for a comprehensive analysis of treatment effects by utilizing 
measures that span the ICF model. 
Procedures 
The assessment and treatment phases of this study were conducted at the Louisiana State 
University (LSU) Speech, Language, and Hearing Clinic. Development of the current protocol 
was completed by the primary investigator under the direction of a certified speech language 
pathologist (SLP) with over 20 years of experience. Administration of the treatment was 
completed by second-year SLP graduate clinicians, under the supervision of a certified SLP with 
over 30 years of experience. The study was conducted in the following manner. 
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During pre-treatment (A1), participants were administered the primary and secondary 
outcome measures (described above). Additionally, four baseline data points were established 
over two sessions for maximum vocal SPL and duration of sustained phonation of vowel /a/ and 
for the control task, which was diadochokinetic rate (i.e., /pʌtʌkʌ/). As is typical in single-
subject designs, a control task was included and was expected to remain unchanged throughout 
all of the phases of the study to assure that changes seen in the dependent variable were effects of 
the treatment and not effects of extraneous variables (Spielman et al., 2007). During the “B” 
phase (i.e., treatment), the same probes were administered at the end of each therapy session, 
yielding a total of 16 data points. Participants completed 45 minutes of therapy, two times per 
week for eight weeks, for a total of 12 hours of therapy. Participants were stable on their 
medications with data collection occurring during an “on” medication cycle.  The time of data 
collection was kept consistent throughout the assessment and treatment phases to reflect the 
same time in the medication cycles of the participants. Also, participants were instructed to 
complete 15 minutes of homework on days that therapy was not received for a total of 10 hours 
over the course of the study. Homework included carryover activities that had been addressed in 
the previous therapy session. The treatment phase was immediately followed by one session of 
post-testing (A2) in which the dependent variable, as well as the primary and the secondary 
outcomes were re-administered. During the 6 months following post-testing (A3), the 
participants did not receive therapy, but were encouraged to continue implementing skills and 
techniques learned during treatment. Postcards were mailed to the clients once every other week 
during the 6-month follow up phase as a reminder to use their newly acquired “loud voice”. 
After 6 months post treatment cessation, follow-up testing, identical to post-testing protocol, 
occurred (see Appendix A). 
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The LSVT
TM
 protocol outlined in Spielman et al. (2007) was followed. Each session 
began with drill on maximum loudness of vowel prolongation, followed by increasingly more 
difficult speech tasks (e.g. words, phrases, sentences, reading paragraphs, conversation). An 
SLP, certified in LSVT
TM
 (Ramig, Pawlas et al., 1995), oversaw the training of the graduate 
clinicians. See Appendix B for complete therapy protocol.  
Data Analysis 
Assessment and treatment was completed in a quiet room at the LSU Speech, Language, 
and Hearing clinic. All primary outcomes measures were audio-recorded using a headset noise-
resistance microphone positioned 2 cm from the participants’ mouths and connected to a Dell 
Optiplex 745 Desktop Computer, which saved the recordings at 48 kHz as a .wav file. To 
measure average vocal SPL of sustained vowel phonation, the participant was instructed to “hold 
/a/ for as long as you can using your normal loudness and voice”. The participant then read “The 
Grandfather Passage” and generated a two-minute monologue using normal loudness. For the 
monologue, participants were given the following instructions: “Talk to me for two minutes 
about the place where you were born and grew up. Please keep talking until I tell you to stop.” 
Analysis of average vocal SPL on all of these tasks was completed using PRAAT software 
(Boersma & Weenink, 2006). Calibration of the software setup was conducted prior to each 
voice recording session by comparing PRAAT values to sound level meter values of generated 
speech noise. All values were within +/- 1.5dBSPL. 
To measure speech intelligibility, participants read ten 14-word sentences from the 
Sentence Intelligibility Test (SIT) from the AIDS. Different sets were used for pre-treatment, 
post- treatment, and follow-up testing to control for listener familiarity during transcription. To 
analyze participants’ productions, an undergraduate student, blind to the study’s purpose, 
transcribed the data in a quiet environment. The transcriber was seated two feet from high-
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quality external speakers, with a desktop computer located directly in front of the transcriber. 
The transcriber received the AIDS transcription instructions to listen to the sentences only two 
times; first listen to the sentence in its entirety, second transcribe while listening, stopping the 
recording as needed . Thereafter, an experienced SLP will scored the SIT according to the AIDS 
manual (Yorkston et al., 1984). 
To measure functional communication, participants completed the CES after being 
provided verbal and written instructions from the PI. Each of the eight items on the CES were 
rated by the participants on a 1-4 scale. The summed CES ratings for each participant were 
converted to interval scores on a 0-100 scale based on Rasch analysis (Donovan et al., 2008). 
Intra-rater reliability was established by the PI reanalyzing the average SPL of three 
randomly selected voice recordings (Urbaniak & Plous, 2009), which reflected 16% of the data 
from primary outcome measures. Inter-rater reliability was established on the intelligibility 
measure. An undergraduate research assistant, blind to the purpose of the study, reanalyzed the 
Sentence Intelligibility Test and three randomly selected scores (Urbaniak & Plous, 2009) were 
compared, which reflected 33% of the data. 
The current study’s research questions were answered by analyzing changes in outcome 
measures and by using visual analysis of the repeated-probe data. Visual analysis was chosen 
because it is not dependent upon the stability of the baseline data points, which is a limitation of 
statistical analysis (Kendall et al., 2008). For visual analysis, the baseline data point stability was 
determined by the PI and was then compared to the relative slope of the treatment data points. 
Due to a small sample size, changes in primary and secondary outcome measures were reported 
descriptively. 
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RESULTS 
Two participants with PD and dysarthria were recruited for this study. The first 
participant, P01, was a 75-year-old Caucasian male. He had received a diagnosis of PD five 
years prior to the start of the current study. The second participant, P02, was a 72-year-old 
Caucasian female. She had received a diagnosis of PD one year prior to the start of the current 
study. Relevant characteristics of the two participants are summarized in Table 3. 
Table 3 
Descriptive characteristics of participants. 
 
 P01 P02 
Age in years 75 72 
Years post-diagnosis 5 1 
MMSE score 30 30 
Apathy Scale rating 9 7 
GDS score 2 0 
Hoehn & Yahr Rating 1 1 
Dysarthria Severity Rating 2 1 
 
Overall, P01 and P02 attended 14 out of 16 therapy sessions, resulting in 10.5 out of a 
possible 12 hours of therapy, due to illness-related absences. Out of the 10 hours of homework 
that was to be completed throughout the course of the study, P01 completed 11 hours of 
homework (44 homework assignments), and P02 completed 8 hours and 45 minutes of 
homework (35 homework assignments). 
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Experimental Questions 
1. Is there a change in vocal sound pressure level (SPL) following an 8-week bout of a 
maximum performance speech therapy (a modified version of LSVT
TM
)? 
Visual analysis was used to analyze change in vocal SPL. For P01, the baseline was 
falling throughout the four baseline measures. The first therapy day data point continued to 
decline at an even more rapid rate. On the second therapy day, the decline stopped and was 
followed by three therapy days with significant increases in vocal SPL. Over the last nine 
therapy sessions, vocal SPL plateaued around the mean of the baseline and remained stable 
(mean: 94.1; range: 92.7-96.5dBSPL). Results from visual analysis indicated an effect was 
observed following this treatment protocol as the falling pattern of the behavior seen in the 
baseline phase was reversed and then stabilized.  
As a control task, diadochokinetic (DDK) rates were also taken at pre-testing, during 
treatment, at post-testing, and at follow up. P01’s baseline DDK rates exhibited random variation 
around a mean of 2.9 syllables/second. The clinician failed to obtain DDK rates on therapy day 
5, and thus, only 13 data points were obtained. Performance over those 13 therapy sessions 
exhibited a stable, random variation around a mean of 3.0 syllables/second. As was expected, 
results indicated therapy was not effective in improving DDK rates. 
The same analysis was used with data from P02. Visually, for P02, the four baseline data 
points exhibited a stable, random variation around a mean of 89.3dBSPL. The baseline period 
was followed by a steady and significant increase in maximum vocal SPL. On the final six days 
of therapy and one day of post-testing, performance plateaued around a mean of 95.9dBSPL 
(range: 94.9-96.7dBSPL). Results indicated a significant effect for improvement of maximum  
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Figure 1 
P01’s maximum vocal SPL from pre-testing, through treatment sessions, post-testing, and 
follow-up. 
 
 
 
 
Figure 2  
P01’s average DDK rate from pre-testing, through treatment sessions, post-testing, and follow-
up. 
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vocal SPL following this treatment protocol as thirteen of the fourteen treatment sessions 
resulted in a vocal SPL higher than the baseline average. 
DDK rates were also obtained for P02 as a control task. P02’s baseline DDK rates 
exhibited random variation around a mean of 2.7 syllables/second. Performance over the 14 
therapy sessions also exhibited a stable, random variation around a mean of 3.1 syllables/second. 
As was expected, results indicated therapy was not effective in improving DDK rates. 
2. Is treatment effect maintained at 6 months post-treatment? 
Visual analysis was also used to determine if treatment effects were maintained six 
months after treatment ceased. Visually, P01’s performance declined significantly, even below 
the baseline mean, and P02’s performance declined to baseline levels. These results indicated 
treatment effects were not maintained six months after therapy was removed. However, the fact 
that the targeted skill (i.e., vocal SPL) declined when therapy was removed speaks to the efficacy 
of the treatment in improving vocal SPL. 
3. Does this dosage produce changes in vocal SPL comparable to increases observed in 
previous LSVT
TM
 studies? 
Similar to previous LSVT
TM
 studies, average vocal SPL of sustained vowel prolongation, 
reading of “The Grandfather Passage” (Darley et al., 1975), and two-minute monologue was 
obtained at pre-testing, post- testing, and follow-up. Average vocal SPL increased from pre-test 
to post-test, and from pre-test to follow-up, for both participants across all SPL outcome 
measures. From pre-test to post-test, P01’s average vocal SPL increased by 83% for sustained 
vowel prolongation, by 35% for Grandfather Passage reading, and by 25% for monologue. From 
pre-test to follow-up, P01’s average vocal SPL increased by 47% for sustained vowel 
prolongation, by 17% for Grandfather Passage reading, and by 12% for monologue. When  
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Figure 3 
P02’s maximum vocal SPL from pre-testing, through treatment sessions, post-testing, and 
follow-up. 
 
 
 
 
Figure 4 
P02’s average DDK rate from pre-testing, through treatment sessions, post-testing, and follow-
up. 
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comparing post-testing to follow-up, all three SPL measures slightly decreased but remained 
above pre-testing levels. 
From pre-test to post-test, P02’s average vocal SPL increased by 20% for sustained 
vowel prolongation, by 18% for Grandfather Passage reading, and by 27% for monologue.  From 
pre-test to follow-up, P02’s average vocal SPL increased by 3% for sustained vowel 
prolongation, by 0.5% for Grandfather Passage reading, and by 7% for monologue.  When 
comparing post-testing to follow-up, all three SPL measures decreased but remained above pre-
testing levels. 
Outcome measures from the current study were directly compared to results from the 
study conducted by Spielman and colleagues (2007). As discussed in the literature review, 
Spielman et al. altered the original LSVT
TM
 protocol to one hour sessions, two times per week 
for eight weeks and termed it LSVT-X. Results from that study were from the average 
performance of 12 participants with idiopathic PD. Comparisons were made to determine how 
the performance of the participants in the current study would compare to the performance of the 
participants in LSVT-X (see Table 4).   
At pre-testing, P01’s performance was statistically lower than the LSVT-X results across 
all three tasks. This indicated P01 exhibited more impairment at the start of the study than did the 
average LSVT-X participant. At post-testing, P01’s scores continued to fall below the mean and 
standard deviation of the LSVT-X results. However, his performance did show a statistically 
significant increase from pre-testing measures that exceeded the increases observed in the  
LSVT-X study. As aforementioned, P01’s performance from pre-to-post-testing increased by 
83% for sustained vowel prolongation, by 35% for Grandfather Passage reading, and by 25% for 
monologue. In comparison, the participants receiving LSVT-X increased by 15% for sustained 
vowel prolongation, by 9% for reading passage, and by 9% for monologue. For P02, her 
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performance was at or below the performance of the LSVT-X participants at pre-testing. At post-
testing, her performance increased to levels at or above that of LSVT-X participants. Results 
indicated a greater increase in therapy outcomes for participants following the current study’s 
protocol than for participants following LSVT-X (Spielman et al., 2007). 
A similarity exists between participants in the current study and participants in the 
LSVT-X study in regards to the difference between pre-test and post-test as compared to follow 
up. In both protocols, participants’ performance decreased from post-testing to follow-up, but 
remained above pre-treatment levels. 
Table 4 
Comparison of P01 and P02’s average vocal SPL to Spielman et al. (2007) results.  
 
 P01 P02 Spielman et al. (2007) 
LSVT-X 
Pre-test    
/a/ 42.32 72.45 72.0 (6.3) 
Grandfather Passage 49.7 63.94 72.7 (3.5) 
Monologue 50.51 57.91 69.6 (2.5) 
Post-test    
/a/ 77.59 87.28 83.0 (3.9) 
Grandfather Passage 67.28 75.46 79.6 (3.3) 
Monologue 63.18 73.26 75.7 (2.6) 
Follow-up    
/a/ 62.33 74.84 82.7 (4.7) 
Grandfather Passage 58.34 64.23 78.7 (3.5) 
Monologue 56.52 61.90 73.7 (2.6) 
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4. Is there a change in speech intelligibility scores following this treatment protocol? 
The Sentence Intelligibility Test from the AIDS (Yorkston et al., 1984) was used to 
measure speech intelligibility. This tool yields a percentage of intelligibility from participants’ 
reading of ten 14-word sentences. From pre-testing to post-testing to follow-up, speech 
intelligibility ratings for P01 were 92%, 99%, and 97.1%, respectively, exhibiting an increase 
from pre-testing to post-testing with a decrease from post-testing to follow-up while remaining 
above pre-testing levels. Speech intelligibility for P02 remained at 100% from pre-testing to 
post-testing and decreased to 98.6% at follow-up (see Table 5). Results indicate this treatment 
protocol positively impacts speech intelligibility for at least one of the participants. 
Table 5 
Speech intelligibility measures for P01 and P02. 
 
 P01 P02 
Pre SIT  92.0% 100.0% 
Post SIT 99.0% 100.0% 
Follow-up SIT 97.1% 98.6% 
 
5. Is there a change in communicative effectiveness ratings following this treatment 
protocol? 
CES ratings were converted from an ordinal to interval scale using Rasch analysis 
(Donovan et al., 2008).  In this study, the interval scale was converted to a 0-100 interval score 
because logit scores may prove difficult for the untrained individual to understand (N. Donovan, 
personal communication, September 7, 2009).  The conversion does not change the measurement 
properties of the instrument or the item difficulty hierarchy.  From pre-testing to post-testing to 
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follow-up, CES ratings for P01 were 52, 69, and 55, respectively, exhibiting an increase from 
pre-testing to post-testing, but a decrease from post-testing to follow-up, although follow-up 
rating remained above pre-testing levels. For P02, CES ratings were 100, 61, and 66 (see Table 
6). Results indicated this treatment protocol positively impacts communicative effectiveness for 
at least one of the participants. The unexpected finding of a decrease from pre-testing to post-
testing for P02 will be discussed in the next section. 
Table 6 
Communicative effectiveness measures for P01 and P02. 
 P01 P02 
Pre CES 52 100 
Post CES 69 61 
Follow-up CES 55 66 
 
Reliability 
Intra-rater reliability was established by the PI reanalyzing the average SPL of three 
randomly selected voice recordings (Urbaniak & Plous, 2009), which reflected 16% of the data 
from primary outcome measures (see Table 7). 
Table 7 
Intra-rater reliability. 
 Actual Score Reviewed Score % Agreement 
Recording 6 57.91 58.01 99.83% 
Recording 7 77.59 77.56 99.96% 
Recording 15 56.52 56.52 100.0% 
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Inter-rater reliability was established on the intelligibility measure. An undergraduate 
research assistant, blind to the purpose of the study, reanalyzed the Sentence Intelligibility Tests, 
and two randomly selected scores (Urbaniak & Plous, 2009) were compared, which reflected 
33% of the data (see Table 8).  
Table 8 
Inter-rater reliability. 
 Actual Score Reviewed Score % Agreement 
SIT 2 99.00 100.00 99.00% 
SIT 4 100.00 98.57 98.57% 
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DISCUSSION 
These preliminary results demonstrate the potential for obtaining a treatment effect using 
a reduced intensity, frequency and duration of the LSVT™ protocol. We achieved these mixed, 
but promising results in less than 12 hours of direct intervention and 40 homework assignments, 
compared to Spielman and colleagues (2007) who demonstrated treatment effects in 16 hours of 
direct intervention and 96 homework assignments, and compared to the original LSVT™ studies 
where results were achieved in 16 hours of direct intervention and 40 homework assignments.  
Both IwPD in the current study exhibited improvement on all primary outcome measures and at 
least one secondary outcome measure.   
Two approaches were taken to examine the effect of treatment on the participants in this 
study, namely treatment efficacy and treatment outcome. There has been much discussion 
regarding the differences and similarities between these two approaches, but as described by 
Olswang (1998), “treatment efficacy research proves treatment benefits; treatment outcome 
research identifies treatment benefits” (pg. 135). Thus, if a treatment is efficacious, one would 
argue that any changes in behavior were the direct result of the treatment administered, which 
come by way of well-controlled studies and rigorous data collection. Outcomes of treatment, on 
the other hand, are measured prior to, during, and after the treatment. The outcomes include 
clinical variables and the benefits of the treatment such as functional improvements the 
participant exhibits.  
The first two research questions of the current study addressed the efficacy of this 
modified LSVT
TM
 protocol. For treatment efficacy in this study, a repeated-probe design was 
used to determine if systematic changes were seen in the participant’s behaviors as the treatment 
was introduced and later withdrawn. As was seen with P01, the treatment protocol not only 
ceased the declining nature of the behavior, but also reversed the behavior to maximum vocal 
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SPLs within normal limits (Ptacek, 1966). More specifically, the decrease in the baseline data 
points suggested that if no treatment had begun, this declining pattern could have continued. At 
the first therapy data point, the behavior continued to fall even further. It must be noted that data 
points were taken at the end of each therapy session, after the treatment protocol had been 
completed. One explanation for the continued decline on the first therapy day for P01 was that 
since it was the first day during which the participant was required to complete high effort 
activities for a full 45-minute session, fatigue set in (as indicated by the low maximum vocal 
SPL). This fatigue factor was slowly eliminated as sessions continued and the participant’s 
ability to complete high effort activities without becoming significantly fatigued increased. P01’s 
maximum vocal SPL, thereafter, increased to and stabilized at a level that fell within normal 
limits for geriatric men (100.5(5.9)dBSPL) (Ptacek, 1966).  
Significant improvements were not visualized for maximum vocal SPL for P01; however, 
a possible explanation for this could be the phenomenon of “ceiling effects.” As is observed in 
studies identifying the normative data on maximum vocal SPL, there is a physiological 
maximum loudness level that under most circumstances cannot be surpassed. An individual can 
get only so loud due to physiological limitations. According to Ptacek et al. (1966), this level for 
healthy geriatric men is 100.5(5.9)dBSPL. P01’s performance fell within this range or within 
2dB of this range for the final 10 therapy sessions, which suggests the treatment moved him to 
his physiological limits and maintained the behavior throughout the remaining course of the 
treatment. The notion that P01’s behavior was maintained at levels within normal limits despite 
the progressive nature of his diagnosis speaks to the efficacy of this treatment. Additionally, 
when treatment was stopped, P01’s maximum vocal SPL six months later decreased. This 
indicated that treatment positively impacted vocal SPL and that effects of this protocol were due 
to the treatment and not extraneous participant variables. These changes in maximum vocal SPL 
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were observed along side an unchanging DDK rate, the control variable, indicating 
improvements in vocal SPL did not come by way of overall participant improvements or by 
chance. Because of this relationship, the data suggests this treatment is efficacious for maximum 
vocal SPL following the current study’s modified LSVTTM protocol. 
From visual analysis, P02’s results indicated treatment efficacy. Stable baseline data 
points gave way to improvement in behavior once treatment was initiated. “Ceiling effects” also 
played a role in the extent to which P02 showed improvement. Ptacek et al. (1966) reported the 
maximum vocal SPL for geriatric women was 98.6(4.5)dBSPL. P02’s performance fell within 
this range or within 2dB of this range for the final 10 therapy sessions, which suggests the 
treatment moved her to her physiological limits and maintained the behavior throughout the 
remaining course of the treatment. As was seen with P01, P02’s performance dropped when 
treatment had been removed for six months, which indicated treatment positively impacted vocal 
SPL and effects of this protocol were due to the treatment and not extraneous participant 
variables. The control variable for P02 also remained relatively unchanged throughout the course 
of the treatment and follow-up testing periods. This indicated that changes in maximum vocal 
SPL were not due to overall participant improvement, chance, or the passage of time. 
More specifically, the second research question, which considers behaviors at a 6-month 
follow-up testing period, presented with mixed results. While the dependent variable, maximum 
vocal SPL, did not demonstrate maintenance of treatment effect after 6-months, the outcome 
measures of this study did. The outcome measure data, which will be discussed next, exhibited a 
significant increase from pre-testing to post-testing and a slight decline from post-testing to 
follow-up. However, follow-up scores remained above pre-treatment levels. These mixed results 
indicated that while the isolated behavior targeted during therapy did not maintain effects once 
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treatment stopped, the functional impacts that this behavior made on the outcome measures 
remained. 
The third research question, with regard to treatment outcomes, examined the benefits of 
the current study’s treatment protocol. Outcome measure results of this study were indeed 
comparable to results from previous studies examining the effects of the LSVT
TM
 protocol on 
vocal SPL. Similar to the results of LSVT-X (Spielman et al., 2007), all three primary outcome 
measures of the current study exhibited substantial increases in vocal SPL from pre-testing to 
post-testing, with slight decreases from post-testing to follow-up. The main difference between 
LSVT-X and the current protocol was the length of individual treatment sessions and the amount 
of assigned homework. Both protocols followed a treatment schedule of sessions twice a week 
for eight weeks. These two protocols are different from the original LSVT
TM
 protocol which 
requires 1-hour sessions four times per week for four weeks (Ramig, Pawlas et al., 1995). While 
the protocol of the current study was designed to require four fewer hours of direct therapy than 
LSVT
TM
 and LSVT-X, actual amount of therapy was even less due to illness-related absences of 
the participants. This resulted in the current study’s protocol having 10.5 hours of direct 
intervention compared to 16 hours of direct intervention following the LSVT
TM
 and LSVT-X 
protocols. Another substantial difference between the protocols was in regards to the amount of 
homework assigned to participants. LSVT
TM
 requires participants to complete 40 assignments, 
and LSVT-X requires participants to complete 96 assignments. Assignments include 5-10 
minutes of practice on days treatment is received and 20-30 minutes on days treatment is not 
received (Ramig, Pawlas et al., 1995; Spielman et al., 2007).  In the current protocol, participants 
were asked to complete 40 homework assignments. More specifically, participants were assigned 
15 minutes of practice on days treatment was not received (10 hours total). P01 completed all 
assigned homework, but P02 only completed 35 assignments despite the close monitoring and 
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consistent encouragement to complete the homework. Although the current protocol required 
less direct intervention and less homework, results of the outcome measures were comparable to 
the LSVT-X protocol, which Spielman and colleagues (2007) found was comparable to the 
original LSVT
TM
 protocol. The current study supports Spielman et al.’s (2007) argument that 
extending practice, both in the clinic and at home, over a longer period of time allows for greater 
consolidation of new motor programs and generalization. Results of this study suggest promising 
results can be achieved following a less intensive treatment protocol that is more in line with 
reimbursement and scheduling issues in a clinical/rehabilitation setting. 
One caveat to the current study and LSVT-X’s protocol is that feedback on homework 
assignments does not occur as often as it does in the original LSVT
TM
 protocol. This lack of 
feedback, especially at the start of intervention, may affect the quality of homework completed 
by the participants. According to the specificity of practice hypothesis, the repeated movement 
patterns an individual practices creates a sensory representation of that specific task (Coull, 
Tremblay, & Elliot, 2001). Thus, if the participant is not provided with enough feedback in the 
early stages of treatment to perform homework assignments in the accurate manner, sensory 
representations different from those created during direct intervention may form, which could 
negatively affect treatment outcomes. 
While the first three research questions address the body structure/function domain of the 
ICF model, the fourth research question targets the activity limitations domain. The secondary 
outcome measure used to address this portion of the ICF was the Sentence Intelligibility Test 
from the AIDS (Yorkston et al., 1984). P01 demonstrated a 9% increase in speech intelligibility 
from pre-testing to post-testing, with a 1.9% decrease from post-testing to follow-up. P02 
demonstrated perfect to near-perfect speech intelligibility at pre-testing, post-testing, and follow-
32 
 
up. Where there was room for improvement, this treatment protocol lead to improvements in the 
activity limitations domain of the ICF model. 
To more closely analyze the changes in P01’s speech intelligibility, this data was 
compared to his other behaviors measured during the course of this study (i.e., maximum vocal 
SPL and DDK rate). The pattern of change for speech intelligibility mirrored the pattern of 
change for P01’s maximum vocal SPL while his DDK rate remained stable throughout the study. 
More specifically, both speech intelligibility and maximum vocal SPL exhibited an increase 
from pre-testing to post-testing, with a decrease from post-testing to follow-up. These results 
suggest that an increase in maximum vocal SPL could alone, without improvements in 
articulatory rate, lead to enhanced speech intelligibility. An explanation for this observation is 
that to increase loudness, an individual must move the mandible to a greater extent and thus the 
vocal tract shape would be altered. This change in vocal tract shape would change vowel 
formants, especially the F2 slope, leading to maximized acoustic distinctiveness and, thus, 
increased speech intelligibility (Tjaden & Wilding, 2004). Some researchers claim that the 
LSVT
TM
 protocol results in improved articulatory function as measured by increases in formant 
slope and rate (Fox et al., 2002). However, results from this study and previous studies suggest 
improvements in speech intelligibility can come solely by way of the effects of increased 
loudness on the vocal tract in the absence of improvements in articulation measures (Halpern et 
al., 2007; Tjaden & Wilding, 2004). 
Another explanation of these results could be that DDK rate does not provide an accurate 
reflection of articulatory function. A great debate exists in regards to whether or not quasi-speech 
tasks, such as DDK, can be used as an accurate measure of speech production skills and 
intelligibility. The two perspectives are one, speech production is a motor behavior similar to any 
other motor behavior that can be broken into component parts and studied, and two, speech 
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production, as a motor behavior, is task specific and tied to tactile and acoustic feedback as well 
as contexts and targets of motor acts (Weismer, 2006). Results of this study are in agreement 
with the latter perspective because P01’s speech intelligibility exhibited improvement in the 
absence of an increase in DDK rate. If, on the other hand, DDK was an accurate measurement of 
speech production skills, DDK rate would be expected to show improvements along side 
improvements in speech intelligibility, which was not the case in the current study. 
With two of the three ICF domains addressed in the first five research questions, the final 
research question focused on the last ICF domain, participation restrictions. The Communicative 
Effectiveness Survey (Donovan et al., 2008) was used to assess this area and showed that this 
treatment protocol lessened participation restrictions in one of the two participants as evidenced 
by an increase in P01’s CES scores from pre-testing to post-testing. P02’s results, on the other 
hand, were an unexpected finding. As mentioned in the results section, her CES rating decreased 
drastically from 100 to 61 from pre-testing to post-testing. It must be noted that P02 explained 
during the post-testing session that the therapy she had completed made her more aware of her 
speech deficits that prior to treatment she had not noticed, as evidenced by her perfect self-rating 
of communicative effectiveness at pre-testing. P02 reported at post-testing that the therapy made 
her more aware of the areas that needed to be improved and the situations in which she needed to 
use her communication strategies in order to be more effective. It must be noted that P02’s CES 
rating increased from post-testing to follow-up, which could indicate this treatment protocol did 
indeed result in an improvement in participation restrictions in P02 as well. 
Limitations 
 The current study was completed during an academic semester at the LSU Speech, 
Language, Hearing Clinic (LSU SLHC). Because of this, the therapy protocol was subject to the 
schedule of the SLHC. Four weeks into the therapy protocol, the SLHC observed a week long 
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break. Thus the 8-week therapy protocol took place over nine weeks. During the one-week 
break, participants were given homework to complete; however there was no direct therapy 
occurring during that week. Also, illness-related absences of the participants resulted in only 14 
sessions of the maximum output speech therapy. In a different setting, the two additional 
sessions could have been made up; however, the SLHC schedule did not allow for the make-up 
sessions. 
Since the LSU SLHC is a teaching facility, another possible limitation of the study was 
the inexperience of the student-clinicians administering the modified LSVT
TM
 therapy protocol. 
The clinicians were second-year graduate students who had not participated in the LSVT
TM
 
training conference but were only trained and supervised by an LSVT
TM
-certified SLP.  This 
may have affected the daily treatment procedures and techniques that were provided to the 
participants. However, despite the lack of official LSVT
TM
 training, treatment was efficacious 
and outcome measures exhibited increases comparable to previous LSVT
TM
 studies (Spielman et 
al., 2007). 
Upon analyzing the data, it appeared as though the participants in this study were perhaps 
not severe enough to allow for large gains to be made in treatment. Initial outcome measures 
indicated that both participants were highly intelligible (i.e., P01: 92%; P02: 100%) and were 
able to produce and to sustain speech within acceptable loudness limits (i.e., P01: 42.43-
50.51dBSPL; P02: 57.91-72.45dBSPL). Because the participant’s abilities were in the mild 
severity range, significant improvements in abilities were unlikely to occur because there was not 
a significant amount of room for improvement. 
Another limitation was that this study obtained four baseline measures but only one post-
testing and one follow-up measure of maximum sustained vowel prolongation in an attempt to be 
more clinically feasible. Although Beeson & Robey (2006) note that only one post-testing and 
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one follow-up measure is mathematically necessary to calculate effect sizes, three data points at 
each of those testing periods would have allowed for a more reliable measure of abilities and 
controlled for variations in participant responses. 
As an additional caveat, the current study’s data are preliminary findings that suggest 
potential treatment efficacy; however, due to the single-subject nature of this study, the results 
lack generalizability.  
Future Studies 
While this was a small single-subject design study, we believe that the preliminary 
results, though mixed, demonstrated the potential for obtaining a treatment effect using a reduced 
LSVT™ protocol. Therefore, it is recommended that the current study be repeated with more 
participants ranging in severity of PD and dysarthria. This would also address the issue of 
“ceiling effects.” IwPD who rate more severe on the Hoehn & Yahr Rating of Parkinson’s 
disease (Hoehn & Yahr, 1967) and the Dysarthria Severity Rating (Yorkston et al., 1999) may 
prove to be better candidates for demonstrating significant improvements following treatment. 
To address the issue of variability of responses at post-testing and follow-up, future 
studies should obtain at least three data points at each of the testing periods.  
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SUMMARY 
In conclusion, a reduction in the intensity, frequency, and duration of the well-known 
LSVT
TM
 protocol to levels more conducive to and realistic in a clinical setting exhibits the 
potential for treatment effects comparable to the original, intensive LSVT
TM
 protocol. The results 
of this preliminary study, though mixed, indicate an increase in vocal SPL during sustained 
vowel prolongation, paragraph reading, and monologue. Additionally, improvements in speech 
intelligibility scores and communicative effectiveness ratings were observed in one of the two 
participants. In regards to the three domains of the ICF model, the reduced levels of the current 
study’s protocol led to improvements in all three domains for P01 and two of the three domains 
for P02.  
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APPENDIX A 
CMOST OUTCOME MEASURES PROTOCOL 
1. Obtain Informed Consent 
2. Record Baseline Data Set 1** 
a. Maximum SPL /a/ 
b. Duration /a/ 
c. Diadochokinetic rate 
3. Record avg SPL of sustained /a/ at normal loudness and pitch 
4. Record avg SPL of reading of “Grandfather Passage” 
5. Record avg SPL of 2 minute monologue of “Where I grew up” 
6. Record Baseline Data Set 2 
7. Record AIDS Sentence Intelligibility measure 
8. Have Client complete CES 
9. Record Baseline Data Set 3 
 
 For baselines, have sound level meter 8 cm from mouth. Use the correct sound level 
meter for that client.  
o Duration of /a/ (This measure and the maximum SPL of /a/ measure can be taken 
simultaneously.) 
 Directions: hold /a/ for as loud and as long as you can. 
 Using a stopwatch, record from voicing onset to offset.  
 Throw out the minimum and maximum duration. Take an average of the 
remaining 8 attempts. Repeat the 10 attempts 3 times (Data Set 1, 2, and 
3) for a total of 30 attempts. 
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o Maximum SPL of /a/ 
 Directions: hold /a/ for as loud and as long as you can 
 Using the sound level meter positioned 8 cm from the client’s mouth, 
record the maximum SPL. 
 Throw out highest maximum SPL and circle the second highest maximum 
SPL of the 10 attempts. Repeat the 10 attempts 3 times (Data Set 1, 2, and 
3) for a total of 30 attempts. 
o Diadochokinetic rate 
 Count the number of times the client can produce “pataka” in 5 seconds. 
 Only count complete productions (i.e., “pata” does not count). 
 Take an average of 3 attempts. Repeat the 3 attempts 3 times (Data Set 1, 
2, and 3) for a total of 9 attempts. 
 For PRAAT recordings (i.e., normal loudness while doing the following tasks: sustained 
/a/, Grandfather passage, 2 minute monologue): 
o Need average SPL for each of these 
o Directions: 
 Place the noise-resistant microphone on the client with microphone at 2 
cm from participant’s mouth. 
 Double click on praat 
 On the “Praat objects” screen, under New select Record Stereo Sound 
 In the Name box, fill in with participant number and task (i.e., 01a, 01GP, 
01mono, 01SI) 
 After the directions are given to the client for a particular task, click 
Record and signal the client to begin the task. 
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 Click Stop when the task is complete. 
 Click Save to list. 
 Repeat these steps for each task (i.e., sustained /a/, grandfather passage, 
etc.) 
 Prior to closing the “Praat objects” screen, you will need to Write these 
files to a folder on the desktop labeled CMOST Data. 
 Click on Write 
 Select Write to WAV file… 
 Select the CMOST Data folder located in the desktop 
 Save as participant number and task (i.e., 01a, 01GP, 01mono, 
01SI) 
o Assure that we control for: 
 Noise reducing microphone 
 Distance from mouth to microphone 
 In lab with door closed 
 Signal input level 
 
**4 baselines will be taken at pre-testing. 1 baseline will be taken at post-testing and 1 at follow-
up testing.  
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APPENDIX B 
CMOST THERAPY PROTOCOL 
Outcomes Measure Day 
 Establish rapport and complete initial interview. Obtain likes/dislikes to be used for 
therapy materials (i.e., single words, phrases, and sentences). 
 Primary investigator will administer outcome measures (see above protocol). 
 
Therapy Day 1  
 Another set of baselines must be taken FIRST thing (see baselines procedures above).  
o 10 attempts of /a/ 
 Duration (average) 
 Maximum SPL 
o 3 diadochokinetic attempts 
 Follow the daily protocol as normal. 
 
Daily Protocol 
 Look over homework form and answer/address any concerns the client had with the 
homework. Place completed homework form in work folder. 
 Complete daily tasks. Coaching should be completed during these tasks. A sound level 
meter can be used during these activities to provide client feedback. Refer to your packet 
for detailed information, but use the following number of attempts. 
o Loud, sustained /a/ (15 repetitions) 
o High and low pitch glides (15 repetitions of each) 
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o 10 Functional sentences (5 repetitions of each) 
o Additional repetitions of any of the above can be completed if there is “extra” 
time. 
 Loud voice should be carried over into the speech hierarchy task. The amount of loudness 
that the patient established in the daily tasks should be transferred to the speech hierarchy 
tasks. A sound level meter can be used throughout these activities to allow for client 
feedback. 
o Week 1 and 2: Single words and phrases 
o Week 3 and 4: Sentences 
o Week 5 and 6: Paragraph Reading 
o Week 7 and 8: Conversation 
 Record Daily data points on CMOST data sheet. See baselines procedures. 
o Elicit 10 productions of a loud, sustained /a/. Record maximum SPL and duration. 
 Directions: hold /a/ for as loud and as long as you can 
o Elicit 3 productions of diadochokinetic activity. Record the number the client can 
produce in 5 seconds. Take an average of the 3 attempts. 
 Assign/review homework. Give client the new homework form (fill in their 10 sentences) 
and a copy of the items you worked on in the speech hierarchy task. 
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